Nuvectis Pharma Inc (NVCT) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-0.34x
Nuvectis Pharma Inc (NVCT) has a Cash Flow-to-Debt Ratio of -0.34x as of June 2026, meaning its operating cash flow of $-4.53 Million could theoretically repay 0% of its total liabilities ($13.29 Million) in one year. See Nuvectis Pharma Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.34x
Operating CF / Total Liabilities
Operating Cash Flow
$-4.53 Million
USD
Total Liabilities
$13.29 Million
USD
Data as of
Jun 2026
Most recent filing
Nuvectis Pharma Inc Cash Flow-to-Debt Ratio (2020–2025)
Historical debt coverage capacity for Nuvectis Pharma Inc across 6 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Nuvectis Pharma Inc.
Annual Cash Flow-to-Debt Ratio for Nuvectis Pharma Inc (2020–2025)
Year-by-year debt coverage analysis for Nuvectis Pharma Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.20x | $-16.01 Million | $13.30 Million | ▲ +12.6% |
| 2024 | -1.38x | $-12.25 Million | $8.89 Million | ▲ +39.7% |
| 2023 | -2.28x | $-15.95 Million | $6.98 Million | ▼ -4.2% |
| 2022 | -2.19x | $-13.56 Million | $6.19 Million | ▼ -307.4% |
| 2021 | -0.54x | $-9.50 Million | $17.66 Million | ▼ -122.4% |
| 2020 | 2.40x | $24.00K | $10.00K | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.